Comparative Pharmacology
Head-to-head clinical analysis: ACCUTANE versus ADAPALENE.
Head-to-head clinical analysis: ACCUTANE versus ADAPALENE.
ACCUTANE vs ADAPALENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and decreases Propionibacterium acnes growth by binding to nuclear retinoic acid receptors, altering gene expression.
Retinoic acid receptor agonist; binds to RARβ/γ nuclear receptors, modulating gene expression to normalize follicular keratinization and reduce comedogenesis.
Isotretinoin 0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks.
Apply a pea-sized amount topically to affected areas once daily in the evening.
None Documented
None Documented
Terminal elimination half-life of isotretinoin is 10-20 hours. The half-life of the major metabolite, 4-oxo-isotretinoin, is 11-50 hours. The long half-life of the metabolite may contribute to sustained clinical effects.
Clinical Note
moderateAdapalene + Gatifloxacin
"Adapalene may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateAdapalene + Rosoxacin
"Adapalene may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateAdapalene + Levofloxacin
"Adapalene may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateAdapalene + Trovafloxacin
"Adapalene may increase the neuroexcitatory activities of Trovafloxacin."
The terminal elimination half-life of adapalene after topical application is approximately 17 hours (range 7–51 hours), reflecting slow release from skin depot and hepatic clearance. This supports once-daily dosing.
Renal and biliary: approximately equal amounts of metabolites are excreted in urine and feces. Unchanged drug is not excreted. Major metabolites: 4-oxo-isotretinoin, tretinoin, 4-oxo-tretinoin. Renal excretion of metabolites accounts for ~65-83% of the dose; fecal excretion accounts for the remainder.
Adapalene is eliminated primarily via biliary excretion into feces. After oral administration in animals, approximately 80% of the dose is recovered in feces and about 10% in urine; for topical application, systemic absorption is minimal and the small absorbed fraction undergoes similar hepatobiliary elimination.
Category C
Category D/X
Retinoid
Retinoid